Brief: Zenas Biopharma And Royalty Pharma Enter Into Obexelimab Funding Agreement For Up To $300 Million
02/09/2025 13:40
Royalty Pharma PLC RPRX.O: ZENAS BIOPHARMA AND ROYALTY PHARMA ENTER INTO OBEXELIMAB FUNDING AGREEMENT FOR UP TO $300 MILLION ROYALTY PHARMA PLC - INITIAL $75 MILLION TO FUND U.S. LAUNCH OF OBEXELIMAB ROYALTY PHARMA PLC - TO RECEIVE 5.5% ROYALTY ON OBEXELIMAB SALES Source text: ID:nGNX3Gl7Kv Further company coverage: RPRX.O
Recent news on Zenas BioPharma
See all newsBrief: Zenas Biopharma Announces Upcoming Presentations Of Obexelimab Data In Igg4-Related Disease At The Igg4ward! 6Th International Symposium On Igg4-Related Disease And Acr Convergence 2026
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints